Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026 in San Francisco on June 11. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has helped accelerate the development of two drug candidates from concept to investigational new drug filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary “manifold folding” technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations, as well as the indexing of approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. Oncotelic said the platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts.
This announcement underscores the growing importance of AI in pharmaceutical R&D. By reducing the typical drug development timeline from over a decade to under two years for IND filings, Oncotelic’s approach could significantly lower costs and bring therapies to patients faster. The platform’s ability to process vast biomedical literature and improve AI accuracy addresses key challenges in drug discovery: information overload and model reliability.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products targeting high-unmet-need cancers and rare pediatric indications. The company also benefits from a robust portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Beyond internal programs, Oncotelic licenses and co-develops drug candidates through strategic partnerships, including a 45% interest in GMP Bio, a joint venture advancing complementary therapeutic candidates.
For more details, view the full press release at https://ibn.fm/Ce72F. The latest news and updates about Oncotelic are available at https://ibn.fm/OTLC.
